Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism LRP1 agonists(LDL receptor related protein 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC34H48N2O3 |
InChIKeyUTKQYACBDGXDMC-UHFFFAOYSA-N |
CAS Registry60168-17-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lung Injury | Phase 2 | - | - | |
Eosinophilic Esophagitis | Preclinical | US | 02 Nov 2023 | |
COVID-19 | Preclinical | US | 01 Dec 2021 | |
Diabetes Mellitus | Preclinical | US | 26 Sep 2013 | |
Acute Kidney Injury | Preclinical | US | - | |
Alopecia Areata | Preclinical | US | - | |
Dermatitis, Atopic | Preclinical | US | - | |
Neuralgia | Preclinical | US | - | |
Inflammation | Discovery | US | 24 Feb 2020 | |
Myocardial Infarction | Discovery | US | 24 Feb 2020 |
Phase 1/2 | 10 | couiujxuyv(wdatbrzfsq) = qkvqaksqjf eqwpxopshs (itzoiehsvw, ugfpeavwbk - ybhakjtmvq) View more | - | 30 Jan 2023 | |||
Phase 1/2 | 10 | (ishrfurqgc) = All ten patients with STEMI received subcutaneous administration of SP16, 381 [272 to 478] minutes after PCI, without any treatment-related adverse events diuxfqocgs (tvmjpmmiwc ) | Positive | 12 Jul 2022 | |||
Placebo | |||||||
NCT03651089 (Pubmed) Manual | Phase 1 | - | 24 | (gcnpvpaoki) = djebqegseq idrpdejfjo (groqfvosdr ) View more | Positive | 06 May 2021 | |
Placebo | (gcnpvpaoki) = tgtsxyzwfu idrpdejfjo (groqfvosdr ) View more |